Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 8/20 | 0.36 |
| ▸ | CES1 | P23141 | 6/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ACLY | P53396 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207954 | 0.79 | FFAR3 (0.43) | FFAR3FAAHCES1CES2MEN1 | |
| SCHEMBL9770794 | 0.78 | TDP1 (0.40) | FFAR3FAAHCES1CES2MEN1 | |
| SCHEMBL9816252 | 0.76 | FAAH (0.34) | FFAR3FAAHCES1CES2MEN1 | |
| SCHEMBL6902350 | 0.76 | FFAR3 (0.38) | FFAR3FAAHCES1CES2MEN1 | |
| SCHEMBL1059264 | 0.74 | ACLY (0.32) | CES1ALDH1A1ACLY | |
| SCHEMBL2468707 | 0.74 | FAAH (0.33) | FFAR3FAAHCES1CES2MEN1 | |
| SCHEMBL458908 | 0.73 | — | — | |
| SCHEMBL8691775 | 0.72 | TSHR (0.40) | CES1ALDH1A1TSHRACLYHIF1A | |
| SCHEMBL5146280 | 0.72 | FAAH (0.67) | FAAHCES1CES2MEN1CYP1A2 | |
| SCHEMBL6117118 | 0.72 | FFAR3 (0.35) | FFAR3FAAHCES1CES2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571854-B1 | METHOD FOR MANUFACTURING 1-ALKYL-3-DIFLUORMETHYL-5-HYDROXYPYRAZOLES | BAYER IP GMBH (DE) | 2014-11-05 | — | — | EP | claimed |
| EP-1362842-B1 | PROCESS FOR PRODUCING 2-FLUORO-3-OXOALKYLCARBOXYLIC ACID ESTER | TOSOH F TECH INC (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-7019162-B2 | Vapor phase fluorination of an oxocarboxylic ester | TOSOH F-TECH, INC. (JP) | 2006-03-28 | — | — | US | disclosed |
| US-20040054217-A1 | Process for preparing 2-fluoro-3-oxoalkylcarboxylic acid ester | TOSOH F-TECH, INC. (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1362842-A1 | PROCESS FOR PRODUCING 2-FLUORO-3-OXOALKYLCARBOXYLIC ACID ESTER | Tosoh F-Tech, Inc. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040054217-A1 | Process for preparing 2-fluoro-3-oxoalkylcarboxylic acid ester | PFAS, ALKBH3, FTO | FFAR3 15/4885FAAH 109/4885CES1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.